尼罗替尼
达沙替尼
医学
髓系白血病
伊马替尼
酪氨酸激酶抑制剂
第一行
酪氨酸激酶
肿瘤科
内科学
癌症
受体
作者
Alfonso Quintás‐Cardama,Elias Jabbour
标识
DOI:10.1016/j.leukres.2013.01.006
摘要
Clinical evidence in chronic myeloid leukemia demonstrates a significant link between optimal response to tyrosine kinase inhibitor (TKI) therapy and favorable clinical outcome. For patients with suboptimal response to first-line TKI, clinical data show that a considerable proportion can be rescued by second-line TKI. Practice guidelines now recommend that clinicians consider a switch in TKI for patients with suboptimal response as early as 3 months after first-line TKI initiation, thus allowing clinicians to intervene in a timely manner and consider the potential benefit of a switch in TKI therapy.
科研通智能强力驱动
Strongly Powered by AbleSci AI